Online inquiry

IVTScrip™ mRNA-Human ARAP3, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK28558MR)

This product GTTS-WK28558MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ARAP3 protein. This product can be used in MKI67+ progenitor cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_022481.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 64411
UniProt ID Q8WWN8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ARAP3, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WK28558MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK12538MR IVTScrip™ mRNA-Human ADGRE3, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ADGRE3
GTTS-WK14962MR IVTScrip™ mRNA-Human ANXA4, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ANXA4
GTTS-WK18970MR IVTScrip™ mRNA-Human AKIRIN2, (Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AKIRIN2
GTTS-WK11644MR IVTScrip™ mRNA-Human ADGRG6, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ADGRG6
GTTS-WK25069MR IVTScrip™ mRNA-Human ARPC4, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARPC4
GTTS-WK23187MR IVTScrip™ mRNA-Human ARHGAP21, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARHGAP21
GTTS-WK13705MR IVTScrip™ mRNA-Human ADAMTS6, (Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ADAMTS6
GTTS-WK11939MR IVTScrip™ mRNA-Human ADGRE5, (Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ADGRE5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW